Correspondence
Atypical Fractures of the Femoral Diaphysis in Postmenopausal Women Taking Alendronate
N Engl J Med 2008; 358:1304-1306March 20, 2008
- Article
To the Editor:
The long-term safety of bisphosphonates for the treatment of osteoporosis has been questioned. Two case series have suggested a link between prolonged bisphosphonate therapy and atypical fractures. In one series, a small number of patients sustained low-energy nonvertebral fractures while receiving long-term alendronate therapy; three were fractures of the femoral shaft.1 Bone biopsies in these patients showed evidence of severely suppressed bone turnover and fracture healing that was delayed or absent. In the other series, low-energy subtrochanteric fractures were found in nine women who had been receiving long-term alendronate therapy.2 Theoretically, bisphosphonates suppress bone turnover and thus might be associated with accumulated microdamage in bone. To our knowledge, no study has demonstrated microdamage accumulation in patients treated with bisphosphonates, and data from studies in animals remain difficult to interpret because supranormal doses of bisphosphonates are used. Nevertheless, the possibility that bisphosphonates alter bone strength with prolonged use appears to exist.
We identified 15 postmenopausal women who had been receiving alendronate for a mean (±SD) of 5.4±2.7 years and who presented with atypical low-energy fractures, defined as fractures occurring in a fall from a standing height or less. All patients sustained subtrochanteric or proximal diaphyseal fractures. Bisphosphonate use was observed in 37% of all patients presenting with low-energy subtrochanteric or diaphyseal fractures. Fractures of the subtrochanteric or diaphyseal regions are relatively rare in postmenopausal women, representing 6% of all osteoporotic hip fractures in our patient population (unpublished data).
Ten of the 15 patients were found to share a unique radiographic pattern, defined as a simple transverse or oblique (≤30°) fracture with beaking of the cortex and diffuse cortical thickening of the proximal femoral shaft. We call this pattern “simple with thick cortices” (Figure 1Figure 1
Radiographs of Fractures of the Femoral Shaft Showing the “Simple with Thick Cortices” Pattern.). These patients had an average duration of alendronate use of 7.3±1.8 years, which was significantly longer than the duration of 2.8±1.3 years for the five patients without this pattern (P<0.001). Cortical thickening was present in the contralateral femur in all the patients with this pattern. Three of the 15 patients had a history of femoral fractures, all in the contralateral femur, whereas no patients had a history of vertebral fractures. Vitamin D and parathyroid hormone measurements and bone densitometry were not performed during fracture care; therefore, we cannot determine the status of the patients with respect to metabolic bone disease.Our results provide further evidence of a potential link between alendronate use and low-energy fractures of the femur. In light of the limitations of our study, a prospective study is indicated. Although many possible explanations exist, patients with the unique radiographic pattern shown here may represent a subgroup of the population that is more susceptible to the effects of prolonged suppression of bone turnover. Additional studies are needed to characterize this subgroup and to establish a clear association between atypical fractures of the femur and prolonged bisphosphonate treatment.
Brett A. Lenart, B.S.
Dean G. Lorich, M.D.
Joseph M. Lane, M.D.
Weill Cornell Medical College, New York, NY 10021
lanej@hss.edu Supported by the Cohn Foundation.
Dr. Lane reports receiving speaking fees from Aventis, GlaxoSmithKline, Eli Lilly, Merck, Novartis, Procter & Gamble, and Roche. No other potential conflict of interest relevant to this letter was reported.
2 References1
Odvina CV ,Zerwekh JE ,Rao DS ,Maalouf N ,Gottschalk FA ,Pak CY . Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab 2005;90:1294-1301
CrossRef | Web of Science | Medline2
Goh SK ,Yang KY ,Koh JS , et al. Subtrochanteric insufficiency fractures in patients on alendronate therapy: a caution. J Bone Joint Surg Br 2007;89:349-353
CrossRef | Web of Science | Medline
- Citing Articles (124)
Citing Articles
1
Katherine J. Motyl, Laurie K. McCauley, Laura R. McCabe. (2012) Amelioration of type I diabetes-induced osteoporosis by parathyroid hormone is associated with improved osteoblast survival. Journal of Cellular Physiology 227:4, 1326-1334
CrossRef2
N. Nicolaou, Y. Agrawal, M. Padman, J. A. Fernandes, M. J. Bell. (2012) Changing pattern of femoral fractures in osteogenesis imperfecta with prolonged use of bisphosphonates. Journal of Children's Orthopaedics
CrossRef3
John R. Fowler, Matthew R. Craig. (2012) Association of Low-energy Femoral Shaft Fractures and Bisphosphonate Use. Orthopedics
CrossRef4
Frieda Feldman. (2012) Atypical diaphyseal femoral fractures—new aspects. Skeletal Radiology 41:1, 75-81
CrossRef5
Jun Iwamoto, Yoshihiro Sato, Mitsuyoshi Uzawa, Tsuyoshi Takeda, Hideo Matsumoto. (2012) Three-year Experience with Alendronate Treatment in Postmenopausal Osteoporotic Japanese Women with or without Renal Dysfunction. Drugs & Aging1
CrossRef6
Celeste J. Hamilton, Sophie A. Jamal, Earl R. Bogoch. 2011. Osteoporosis and Metabolic Disorders. , 35-55.
CrossRef7
Jonathan D. Adachi, Kenneth Lyles, Steven Boonen, Cathleen Colón-Emeric, Lars Hyldstrup, Lars Nordsletten, Carl Pieper, Chris Recknor, Guoqin Su, Christina Bucci-Rechtweg, Jay Magaziner. (2011) Subtrochanteric Fractures in Bisphosphonate-Naive Patients: Results from the HORIZON-Recurrent Fracture Trial. Calcified Tissue International 89:6, 427-433
CrossRef8
R. Lenz, M. Ellenrieder, R. Skripitz, R. Bader, C. Pautke, W. Mittelmeier, T. Tischer. (2011) Bisphosphonatinduzierte Stressfrakturen am Femur. Der Orthopäde 40:12, 1111-1118
CrossRef9
L.J. Kidd, N.R. Cowling, A.C.K. Wu, W.L. Kelly, M.R. Forwood. (2011) Bisphosphonate treatment delays stress fracture remodeling in the rat ulna. Journal of Orthopaedic Research 29:12, 1827-1833
CrossRef10
Rami El Rachkidi, Marie-Laure Sari-Leret, Stephane Wolff. (2011) Atypical Bilateral Pedicle Fracture in Long-Term Bisphosphonate Therapy. Spine 36:26, E1769-E1773
CrossRef11
Maurice Audran, Bernard Cortet, Thierry Thomas. (2011) What do we know about atypical femoral fractures? Insights and enigmas. Joint Bone Spine 78:6, 568-571
CrossRef12
Crystal K. Tjhia, Clarita V. Odvina, D. Sudhaker Rao, Susan M. Stover, Xiang Wang, David P. Fyhrie. (2011) Mechanical property and tissue mineral density differences among severely suppressed bone turnover (SSBT) patients, osteoporotic patients, and normal subjects. Bone 49:6, 1279-1289
CrossRef13
Robert R. Recker. (2011) Early postmenopausal bone loss and what to do about it. Annals of the New York Academy of Sciences 1240:1, E26-E30
CrossRef14
A. Zarza Pérez, J. L. Martín Alguacil, B. Campos Melenchón, A. D. Delgado Martínez. (2011) Low-energy spontaneous femoral fractures in patients with long-term bisphosphonate therapy. European Journal of Orthopaedic Surgery & Traumatology
CrossRef15
Marie-Paule Lecart, Jean-Yves Reginster. (2011) Current options for the management of postmenopausal osteoporosis. Expert Opinion on Pharmacotherapy 12:16, 2533-2552
CrossRef16
Pongthorn Narongroeknawin, Nivedita M. Patkar, Bita Shakoory, Archana Jain, Jeffrey R. Curtis, Elizabeth Delzell, Philip H. Lander, Robert R. Lopez-Ben, Michael J. Pitt, Monika M. Safford, David A. Volgas, Kenneth G. Saag. (2011) Validation of Diagnostic Codes for Subtrochanteric, Diaphyseal, and Atypical Femoral Fractures Using Administrative Claims Data. Journal of Clinical Densitometry
CrossRef17
Kazuo Ishizuna, Daisuke Ota, Atsushi Fukuuchi, Megumi Teraoka, Akiko Fujii, Masaya Mori, Tsunehiro Nishi. (2011) A case of femoral diaphyseal fracture after long-term treatment with zoledronic acid. Breast Cancer
CrossRef18
Judith M. E. Walsh, Megan McNamara, Redonda G. Miller, Eleanor Bimla Schwarz. (2011) Update in Women’s Health for the General Internist. Journal of General Internal Medicine
CrossRef19
G. Bianchi, E. Czerwinski, A. Kenwright, A. Burdeska, R. R. Recker, D. Felsenberg. (2011) Long-term administration of quarterly IV ibandronate is effective and well tolerated in postmenopausal osteoporosis: 5-year data from the DIVA study long-term extension. Osteoporosis International
CrossRef20
Frank A. Liporace, Richard S. Yoon, Matthew A. Frank, James P. Maurer, Robert J. Gaines. (2011) Single-Stage Total Hip Arthroplasty and Fracture Fixation for a Both Column Acetabular Fracture in Type I Osteogenesis Imperfecta. Injury 42:10, 1184-1187
CrossRef21
Maurice Audran, Bernard Cortet, Thierry Thomas. (2011) Que sait-on des fractures fémorales atypiques ? Entre progrès et inconnues. Revue du Rhumatisme 78:5, 423-426
CrossRef22
Thomas Funck-Brentano, Emmanuel Biver, Florence Chopin, Beatrice Bouvard, Guillaume Coiffier, Jean-Claude Souberbielle, Patrick Garnero, Christian Roux. (2011) Clinical Utility of Serum Bone Turnover Markers in Postmenopausal Osteoporosis Therapy Monitoring: A Systematic Review. Seminars in Arthritis and Rheumatism 41:2, 157-169
CrossRef23
Jian Sheng Chen, Philip N. Sambrook. (2011) Antiresorptive therapies for osteoporosis: a clinical overview. Nature Reviews Endocrinology
CrossRef24
Ian R. Reid. (2011) Bisphosphonates in the treatment of osteoporosis: a review of their contribution and controversies. Skeletal Radiology 40:9, 1191-1196
CrossRef25
, C. Colón-Emeric, L. Nordsletten, S. Olson, N. Major, S. Boonen, P. Haentjens, P. Mesenbrink, J. Magaziner, J. Adachi, K. W. Lyles, L. Hyldstrup, C. Bucci-Rechtweg, C. Recknor. (2011) Association between timing of zoledronic acid infusion and hip fracture healing. Osteoporosis International 22:8, 2329-2336
CrossRef26
Robert R. Recker, Laura Armas. (2011) The Effect of Antiresorptives on Bone Quality. Clinical Orthopaedics and Related Research® 469:8, 2207-2214
CrossRef27
Jun Iwamoto, Yoshihiro Sato, Mitsuyoshi Uzawa, Tsuyoshi Takeda, Hideo Matsumoto. (2011) Three-year experience with alendronate treatment in postmenopausal osteoporotic Japanese women with or without type 2 diabetes. Diabetes Research and Clinical Practice 93:2, 166-173
CrossRef28
Roger H Jay, Sarah L Marrinan. (2011) Osteoporosis treatment and the older patient. Reviews in Clinical Gerontology 21:03, 233-245
CrossRef29
Jie Zhang, Kenneth G. Saag, Jeffrey R. Curtis. (2011) Long-term Safety Concerns of Antiresorptive Therapy. Rheumatic Disease Clinics of North America 37:3, 387-400
CrossRef30
Yoram A. Weil, Gurion Rivkin, Ori Safran, Meir Liebergall, A. Joseph Foldes. (2011) The Outcome of Surgically Treated Femur Fractures Associated With Long-Term Bisphosphonate Use. The Journal of Trauma: Injury, Infection, and Critical Care 71:1, 186-190
CrossRef31
Michael Pazianas, Bo Abrahamsen. (2011) Safety of bisphosphonates. Bone 49:1, 103-110
CrossRef32
Sok Chuen Tan, Suang Bee Joyce Koh, Seo Kiat Goh, Tet Sen Howe. (2011) Atypical femoral stress fractures in bisphosphonate-free patients. Osteoporosis International 22:7, 2211-2212
CrossRef33
Mikko T. Ovaska, Tatu J. Mäkinen, Rami Madanat. (2011) Simultaneous bilateral subtrochanteric fractures following risedronate therapy. Journal of Orthopaedic Science 16:4, 467-470
CrossRef34
Joong Kyong Ahn, Jaejoon Lee, Hoon-Suk Cha, Eun-Mi Koh. (2011) Non-traumatic fracture of the femoral shaft in a patient taking long-term bisphosphonate therapy. Rheumatology International 31:7, 973-975
CrossRef35
Michael B. Banffy, Mark S. Vrahas, John E. Ready, John A. Abraham. (2011) Nonoperative versus Prophylactic Treatment of Bisphosphonate-associated Femoral Stress Fractures. Clinical Orthopaedics and Related Research® 469:7, 2028-2034
CrossRef36
Erik Fink Eriksen. (2011) Treatment of osteopenia. Reviews in Endocrine and Metabolic Disorders
CrossRef37
Christopher J Yates, Miriam J Bartlett, Peter R Ebeling. (2011) An atypical subtrochanteric femoral fracture from pycnodysostosis: A lesson from nature. Journal of Bone and Mineral Research 26:6, 1377-1379
CrossRef38
Brian J. Gates, Shyamal Das. (2011) Management of osteoporosis in elderly men. Maturitas 69:2, 113-119
CrossRef39
R. Eastell, A. Rogers, X. Ni, J. H. Krege. (2011) Effects of raloxifene and alendronate on bone turnover as assessed by procollagen type I N-terminal propeptide. Osteoporosis International 22:6, 1927-1934
CrossRef40
Yoshitomo Kajino, Tamon Kabata, Koji Watanabe, Hiroyuki Tsuchiya. (2011) Histological finding of atypical subtrochanteric fracture after long-term alendronate therapy. Journal of Orthopaedic Science
CrossRef41
Schilcher, Jörg, Michaëlsson, Karl, Aspenberg, Per, . (2011) Bisphosphonate Use and Atypical Fractures of the Femoral Shaft. New England Journal of Medicine 364:18, 1728-1737
Full Text42
Bo Abrahamsen. (2011) Bone freezing and bisphosphonates. Maturitas 69:1, 1-2
CrossRef43
Oxana Kamneva, Ann Marie Nye, Irene Hamrick. (2011) Reasons for Bisphosphonate Exclusion in Patients Treated for Osteoporosis. The Consultant Pharmacist 26:5, 325-331
CrossRef44
Christian M. Girgis, Markus J. Seibel. (2011) Guilt by association? Examining the role of bisphosphonate therapy in the development of atypical femur fractures. Bone 48:5, 963-965
CrossRef45
Seo Young Kim, Sebastian Schneeweiss, Jeffrey N Katz, Raisa Levin, Daniel H Solomon. (2011) Oral bisphosphonates and risk of subtrochanteric or diaphyseal femur fractures in a population-based cohort. Journal of Bone and Mineral Research 26:5, 993-1001
CrossRef46
Chris Recknor. (2011) Zoledronic acid for prevention and treatment of osteoporosis. Expert Opinion on Pharmacotherapy 12:5, 807-815
CrossRef47
Sigrun Ressler, Brigitte Mlineritsch, Richard Greil. (2011) Zoledronic acid for adjuvant use in patients with breast cancer. Expert Review of Anticancer Therapy 11:3, 333-349
CrossRef48
Zhong Wang, Timothy Bhattacharyya. (2011) Trends in Incidence of Subtrochanteric Fragility Fractures and Bisphosphonate Use Among the US Elderly, 1996-2007. Journal of Bone and Mineral Research 26:3, 553-560
CrossRef49
Peter Vestergaard, Lars Rejnmark, Leif Mosekilde. (2011) Are Antiresorptive Drugs Effective Against Fractures in Patients with Diabetes?. Calcified Tissue International 88:3, 209-214
CrossRef50
Meghan E. McGee-Lawrence, Jennifer J. Westendorf. (2011) Histone deacetylases in skeletal development and bone mass maintenance. Gene 474:1-2, 1-11
CrossRef51
P. Vestergaard, F. Schwartz, L. Rejnmark, L. Mosekilde. (2011) Risk of femoral shaft and subtrochanteric fractures among users of bisphosphonates and raloxifene. Osteoporosis International 22:3, 993-1001
CrossRef52
Ioannis Charopoulos, Steve Orme, Peter V Giannoudis. (2011) The role and efficacy of denosumab in the treatment of osteoporosis: an update. Expert Opinion on Drug Safety 10:2, 205-217
CrossRef53
R. Tamai, A. Sugiyama, Y. Kiyoura. (2011) Alendronate regulates cytokine production induced by lipid A through nuclear factor-κB and Smad3 activation in human gingival fibroblasts. Journal of Periodontal Research 46:1, 13-20
CrossRef54
Steven L. Teitelbaum, Margaret P. Seton, Kenneth G. Saag. (2011) Should bisphosphonates be used for long-term treatment of glucocorticoid-induced osteoporosis?. Arthritis & Rheumatism 63:2, 325-328
CrossRef55
R. Rizzoli, K. Åkesson, M. Bouxsein, J. A. Kanis, N. Napoli, S. Papapoulos, J.-Y. Reginster, C. Cooper. (2011) Subtrochanteric fractures after long-term treatment with bisphosphonates: a European Society on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis, and International Osteoporosis Foundation Working Group Report. Osteoporosis International 22:2, 373-390
CrossRef56
Kimberly McKenzie, J. Dennis Bobyn, Jacintha Roberts, Dorota Karabasz, Michael Tanzer. (2011) Bisphosphonate Remains Highly Localized After Elution From Porous Implants. Clinical Orthopaedics and Related Research® 469:2, 514-522
CrossRef57
Kousuke Iba, Junichi Takada, Koichi Sasaki, Takuro Wada, Toshihiko Yamashita. (2011) Course of NTX changes under continuous bisphosphonate treatment in cases of NTX over-reduction due to long-term treatment with bisphosphonates. Journal of Orthopaedic Science 16:1, 71-76
CrossRef58
Frederick R. Singer. (2011) Metabolic bone disease: Atypical femoral fractures. Journal of Biomechanics 44:2, 244-247
CrossRef59
Mary Kamienski, Denise Tate, CPT Marielos Vega. (2011) The Silent Thief. Orthopaedic Nursing 30:3, 162-171
CrossRef60
Tero Yli-Kyyny. (2011) Bisphosphonates and Atypical Fractures of Femur. Journal of Osteoporosis 2011, 1-5
CrossRef61
Yasuhisa Abe, Kousuke Iba, Junichi Takada, Takuro Wada, Toshihiko Yamashita. (2011) Improvement of pain and regional osteoporotic changes in the foot and ankle by low-dose bisphosphonate therapy for complex regional pain syndrome type I: a case series. Journal of Medical Case Reports 5:1, 349
CrossRef62
K. Briot. (2011) Osteoporosis posmenopáusica. EMC - Aparato Locomotor 44:4, 1-11
CrossRef63
Joseph D. Isaacs, Louis Shidiak, Ian A. Harris, Zoltan L. Szomor. (2010) Femoral Insufficiency Fractures Associated with Prolonged Bisphosphonate Therapy. Clinical Orthopaedics and Related Research® 468:12, 3384-3392
CrossRef64
Elizabeth Shane, David Burr, Peter R Ebeling, Bo Abrahamsen, Robert A Adler, Thomas D Brown, Angela M Cheung, Felicia Cosman, Jeffrey R Curtis, Richard Dell, David Dempster, Thomas A Einhorn, Harry K Genant, Piet Geusens, Klaus Klaushofer, Kenneth Koval, Joseph M Lane, Fergus McKiernan, Ross McKinney, Alvin Ng, Jeri Nieves, Regis O'Keefe, Socrates Papapoulos, Howe Tet Sen, Marjolein CH van der Meulen, Robert S Weinstein, Michael Whyte. (2010) Atypical subtrochanteric and diaphyseal femoral fractures: Report of a task force of the american society for bone and mineral Research. Journal of Bone and Mineral Research 25:11, 2267-2294
CrossRef65
Vishal C. Patel, Adam M. Lazzarini. (2010) Bilateral Simultaneous Femoral Diaphyseal Fractures in a Patient with Long-Term Ibandronate Use. Orthopedics
CrossRef66
J.-J. Body, P. Bergmann, S. Boonen, Y. Boutsen, J.-P. Devogelaer, S. Goemaere, J.-M. Kaufman, S. Rozenberg, J.-Y. Reginster. (2010) Evidence-based guidelines for the pharmacological treatment of postmenopausal osteoporosis: a consensus document by the Belgian Bone Club. Osteoporosis International 21:10, 1657-1680
CrossRef67
David M. Reid. (2010) Update on the Use of Zoledronic Acid in the Management of Osteoporosis. Current Osteoporosis Reports 8:3, 145-150
CrossRef68
Marcy B. Bolster. (2010) Osteoporosis and Bone Health in Patients with Lung Disease. Clinics in Chest Medicine 31:3, 555-563
CrossRef69
Andrea Giusti, Neveen A.T. Hamdy, Socrates E. Papapoulos. (2010) Atypical fractures of the femur and bisphosphonate therapy. Bone 47:2, 169-180
CrossRef70
Ishir Bhan, Anil Dubey, Myles Wolf. (2010) Diagnosis and Management of Mineral Metabolism in CKD. Journal of General Internal Medicine 25:7, 710-716
CrossRef71
Shane, Elizabeth, . (2010) Evolving Data about Subtrochanteric Fractures and Bisphosphonates. New England Journal of Medicine 362:19, 1825-1827
Full Text72
Girgis, Christian M., Sher, Doron, Seibel, Markus J., . (2010) Atypical Femoral Fractures and Bisphosphonate Use. New England Journal of Medicine 362:19, 1848-1849
Full Text73
Black, Dennis M., Kelly, Michael P., Genant, Harry K., Palermo, Lisa, Eastell, Richard, Bucci-Rechtweg, Christina, Cauley, Jane, Leung, Ping Chung, Boonen, Steven, Santora, Arthur, de Papp, Anne, Bauer, Douglas C., . (2010) Bisphosphonates and Fractures of the Subtrochanteric or Diaphyseal Femur. New England Journal of Medicine 362:19, 1761-1771
Full Text74
Laurent Maïmoun, Tara C. Brennan, Isabelle Badoud, Victor Dubois-Ferriere, René Rizzoli, Patrick Ammann. (2010) Strontium ranelate improves implant osseointegration. Bone 46:5, 1436-1441
CrossRef75
Mohammad Shahnazari, Wei Yao, WeiWei Dai, Bob Wang, Sophi S. Ionova-Martin, Robert O. Ritchie, Daniel Heeren, Andrew J. Burghardt, Daniel P. Nicolella, Michael G. Kimiecik, Nancy E. Lane. (2010) Higher doses of bisphosphonates further improve bone mass, architecture, and strength but not the tissue material properties in aged rats. Bone 46:5, 1267-1274
CrossRef76
Clifford J Rosen. (2010) Exploiting new targets for old bones. Journal of Bone and Mineral Research 25:5, 934-936
CrossRef77
Richard S. Yoon, Kathleen S. Beebe, Joseph Benevenia. (2010) Prophylactic Bilateral Intramedullary Femoral Nails for Bisphosphonate-Associated Signs of Impending Subtrochanteric Hip Fracture. Orthopedics
CrossRef78
M. H. Edwards, F. C. McCrae, S. A. Young-Min. (2010) Alendronate-related femoral diaphysis fracture—what should be done to predict and prevent subsequent fracture of the contralateral side?. Osteoporosis International 21:4, 701-703
CrossRef79
N. Napoli, D. Novack, R. Armamento-Villareal. (2010) Bisphosphonate-associated femoral fracture: implications for management in patients with malignancies. Osteoporosis International 21:4, 705-708
CrossRef80
Samuel Gourion-Arsiquaud, Matthew R. Allen, David B. Burr, Deepak Vashishth, Simon Y. Tang, Adele L. Boskey. (2010) Bisphosphonate treatment modifies canine bone mineral and matrix properties and their heterogeneity. Bone 46:3, 666-672
CrossRef81
Chandrasekar Palaniswamy, Dhana Rekha Selvaraj, Varuni Rao, Umesh Patel. (2010) Newer Therapies for Osteoporosis. American Journal of Therapeutics 17:2, 197-200
CrossRef82
J. W. Nieves, J. P. Bilezikian, J. M. Lane, T. A. Einhorn, Y. Wang, M. Steinbuch, F. Cosman. (2010) Fragility fractures of the hip and femur: incidence and patient characteristics. Osteoporosis International 21:3, 399-408
CrossRef83
Clarita V. Odvina, Shiri Levy, Sudhir Rao, Joseph E. Zerwekh, D. S. Rao. (2010) Unusual mid-shaft fractures during long-term bisphosphonate therapy. Clinical Endocrinology 72:2, 161-168
CrossRef84
J. Goldhahn, D. Little, P. Mitchell, N.L. Fazzalari, I.R. Reid, P. Aspenberg, D. Marsh. (2010) Evidence for anti-osteoporosis therapy in acute fracture situations—Recommendations of a multidisciplinary workshop of the International Society for Fracture Repair. Bone 46:2, 267-271
CrossRef85
Robert D. Bunning, Robert J. Rentfro, James S. Jelinek. (2010) Low-Energy Femoral Fractures Associated With Long-Term Bisphosphonate Use in a Rehabilitation Setting: A Case Series. PM&R 2:1, 76-80
CrossRef86
Hyoung Moo Park. (2010) Current use of drugs for osteoporosis in Korea. Korean Journal of Obstetrics and Gynecology 53:2, 152
CrossRef87
Athanassios Kyrgidis, Konstantinos Vahtsevanos. (2009) “Fatigue” having a role in the pathogenesis of osteonecrosis of the jaws. Clinical Oral Investigations 13:4, 479-480
CrossRef88
Per Aspenberg. (2009) Bisphosphonates and fatigue fractures. IBMS BoneKEy 6:12, 465-469
CrossRef89
Peter R. Ebeling. (2009) Metabolic bone diseases: Translational research—preventing fractures with denosumab. Nature Reviews Rheumatology 5:12, 660-661
CrossRef90
Cameron Y.S. Lee, Jon B. Suzuki. (2009) CTX Biochemical Marker of Bone Metabolism. Is it a Reliable Predictor of Bisphosphonate-Associated Osteonecrosis of the Jaws After Surgery? Part I: Biological Concepts With a Review of the Literature. Implant Dentistry 18:6, 492-500
CrossRef91
David B. Burr, Tamim Diab, Andrew Koivunemi, Mark Koivunemi, Matthew R. Allen. (2009) Effects of 1 to 3 years' treatment with alendronate on mechanical properties of the femoral shaft in a canine model: Implications for subtrochanteric femoral fracture risk. Journal of Orthopaedic Research 27:10, 1288-1292
CrossRef92
T. Ali, R. H. Jay. (2009) Spontaneous femoral shaft fracture after long-term alendronate. Age and Ageing 38:5, 625-626
CrossRef93
C. Bergot, Y. Wu, E. Jolivet, L.Q. Zhou, J.D. Laredo, V. Bousson. (2009) The degree and distribution of cortical bone mineralization in the human femoral shaft change with age and sex in a microradiographic study. Bone 45:3, 435-442
CrossRef94
Kuntheavy Ing-Lorenzini, Jules Desmeules, Olivier Plachta, Domizio Suva, Pierre Dayer, Robin Peter. (2009) Low-Energy Femoral Fractures Associated with the Long-Term Use of Bisphosphonates. Drug Safety 32:9, 775-785
CrossRef95
Khosla, Sundeep, . (2009) Increasing Options for the Treatment of Osteoporosis. New England Journal of Medicine 361:8, 818-820
Full Text96
(2009) Chapter 4.1: Treatment of CKD–MBD targeted at lowering high serum phosphorus and maintaining serum calcium. Kidney International 76, S50-S99
CrossRef97
R. D. Chapurlat, P. D. Delmas. (2009) Bone microdamage: a clinical perspective. Osteoporosis International 20:8, 1299-1308
CrossRef98
S. D. Vasikaran. (2009) Association of low-energy femoral fractures with prolonged bisphosphonate use: a case--control study. Osteoporosis International 20:8, 1457-1458
CrossRef99
Maria S. Goddard, Kristoff R. Reid, James C. Johnston, Harpal S. Khanuja. (2009) Atraumatic Bilateral Femur Fracture in Long-Term Bisphosphonate Use. Orthopedics 32:8, 607-610
CrossRef100
B. A. Lenart, A. S. Neviaser, S. Lyman, C. C. Chang, F. Edobor-Osula, B. Steele, M. C. H. Meulen, D. G. Lorich, J. M. Lane. (2009) Association of low-energy femoral fractures with prolonged bisphosphonate use: a case control study. Osteoporosis International 20:8, 1353-1362
CrossRef101
Athanassios Kyrgidis, Stefanos Triaridis, Kostantinos Vahtsevanos, Kostantinos Antoniades. (2009) Osteonecrosis of the jaw and bisphosphonate use in breast cancer patients. Expert Review of Anticancer Therapy 9:8, 1125-1134
CrossRef102
Arkan S. Sayed-Noor, Göran O. Sjödén. (2009) Case Reports: Two Femoral Insufficiency Fractures after Long-term Alendronate Therapy. Clinical Orthopaedics and Related Research® 467:7, 1921-1926
CrossRef103
Daniel H Solomon, Laura Rekedal, Suzanne M Cadarette. (2009) Osteoporosis treatments and adverse events. Current Opinion in Rheumatology 21:4, 363-368
CrossRef104
Kurt A. Kennel, Matthew T. Drake. (2009) Adverse Effects of Bisphosphonates: Implications for Osteoporosis Management. Mayo Clinic Proceedings 84:7, 632-638
CrossRef105
Reina Armamento-Villareal, Nicola Napoli, Kathryn Diemer, Marcus Watkins, Roberto Civitelli, Steven Teitelbaum, Deborah Novack. (2009) Bone Turnover in Bone Biopsies of Patients with Low-Energy Cortical Fractures Receiving Bisphosphonates: A Case Series. Calcified Tissue International 85:1, 37-44
CrossRef106
K. A. Kennel, M. T. Drake. (2009) Adverse Effects of Bisphosphonates: Implications for Osteoporosis Management. Mayo Clinic Proceedings 84:7, 632-638
CrossRef107
Yosuke Shima, Lars Engebretsen, Junji Iwasa, Katsuhiko Kitaoka, Katsuro Tomita. (2009) Use of bisphosphonates for the treatment of stress fractures in athletes. Knee Surgery, Sports Traumatology, Arthroscopy 17:5, 542-550
CrossRef108
A. L. Boskey, L. Spevak, R. S. Weinstein. (2009) Spectroscopic markers of bone quality in alendronate-treated postmenopausal women. Osteoporosis International 20:5, 793-800
CrossRef109
P. Makras, N.A.T. Hamdy, A.H. Zwinderman, B.E.P.B. Ballieux, S.E. Papapoulos. (2009) Bisphosphonate dose and incidence of fractures in postmenopausal osteoporosis. Bone 44:5, 766-771
CrossRef110
Ingrid Ekenman. (2009) Do not use bisphosphonates without scientific evidence, neither in treatment nor prophylactic, in the treatment of stress fractures. Knee Surgery, Sports Traumatology, Arthroscopy 17:5, 433-434
CrossRef111
Maryann Napoli. (2009) The Marketing of Osteoporosis. AJN, American Journal of Nursing 109:4, 58-61
CrossRef112
E. Michael Lewiecki, Sanford Baim, John P. Bilezikian, Richard Eastell, Meryl S. LeBoff, Paul D. Miller. (2009) 2008 Santa Fe Bone Symposium: Update on Osteoporosis. Journal of Clinical Densitometry 12:2, 135-157
CrossRef113
Jonathan M. Grasko, Richard P. Herrmann, Samuel D. Vasikaran. (2009) Recurrent Low-Energy Femoral Shaft Fractures and Osteonecrosis of the Jaw in a Case of Multiple Myeloma Treated With Bisphosphonates. Journal of Oral and Maxillofacial Surgery 67:3, 645-649
CrossRef114
Salvatore L. Ruggiero, Bhoomi Mehrotra. (2009) Bisphosphonate-Related Osteonecrosis of the Jaw: Diagnosis, Prevention, and Management. Annual Review of Medicine 60:1, 85-96
CrossRef115
E. Romas. (2009) Clinical applications of RANK-ligand inhibition. Internal Medicine Journal 39:2, 110-116
CrossRef116
Takaaki Tanaka, Mitsuru Saito, Masaaki Chazono, Yoshio Kumagae, Takahiro Kikuchi, Seiichiro Kitasato, Keishi Marumo. (2009) Effects of alendronate on bone formation and osteoclastic resorption after implantation of beta-tricalcium phosphate. Journal of Biomedical Materials Research Part A 9999A, NA-NA
CrossRef117
Jörg Schilcher, Per Aspenberg. (2009) Incidence of stress fractures of the femoral shaft in women treated with bisphosphonate. Acta Orthopaedica 80:4, 413-415
CrossRef118
Leyla H. Alparslan, Barbara N. Weissman. 2009. Imaging Findings of Drug-Related Musculoskeletal Disorders. , 264-279.
CrossRef119
Seth M Arum. (2008) New developments surrounding the safety of bisphosphonates. Current Opinion in Endocrinology, Diabetes and Obesity 15:6, 508-513
CrossRef120
Socrates E. Papapoulos. (2008) Bisphosphonates: how do they work?. Best Practice & Research Clinical Endocrinology & Metabolism 22:5, 831-847
CrossRef121
Michael Samoszuk, Michael Leuther, Nicholas Hoyle. (2008) Role of serum P1NP measurement for monitoring treatment response in osteoporosis. Biomarkers in Medicine 2:5, 495-508
CrossRef122
(2008) Current awareness: Pharmacoepidemiology and drug safety. Pharmacoepidemiology and Drug Safety 17:9, i-xvi
CrossRef123
(2008) More on Atypical Fractures of the Femoral Diaphysis. New England Journal of Medicine 359:3, 316-318
Full Text124
Joel Shuster. (2008) ISMP Adverse Drug Reactions - Heart Failure With Sunitinib; Prolonged QT Interval, Syncope, and Delirium With Galantamine; Memantine-Induced Hepatitis; Cabergoline-Associated Erythema Nodosum; “Sleep Driving” and the Use of Nonbenzodiazepine Hypnotics; Atypical Fractures in Postmenopausal Women Taking Alendronate; Drug-Related Problems in Patients With Human Immunodeficiency Virus. Hospital Pharmacy 43:6, 449-452
CrossRef
- Letters
